Biological staging of Alzheimer's disease with the novel plasma eMTBR‐tau243 and %p‐tau217
The combination of plasma %p-tau217 and eMTBR-tau243 and facilitates accurate biological staging of AD. This plasma-based approach is non-invasive, scalable, and offers a more practical alternative to cerebrospinal fluid or PET-based staging methods.
Authors
- Divya Bali (ORCID: https://orcid.org/0000-0003-3178-1586)
- Rik Ossenkoppele (ORCID: https://orcid.org/0000-0003-1584-7477)
- Erik Stomrud (ORCID: https://orcid.org/0000-0002-0841-5580)
- Anna Orduña Dolado (ORCID: https://orcid.org/0009-0003-8287-0754)
- Gemma Salvadó (ORCID: https://orcid.org/0000-0002-5210-9230)
- Kanta Horie (ORCID: https://orcid.org/0000-0001-7736-2614)
- Oskar H. Hansson
- Niklas Mattsson‐Carlgren
- Sebastian Palmqvist
- Randall J. Bateman
- Shorena Janelidze
- Nicolas R. Barthélemy
- Jacob W. Vogel
- Suzanne E. Schindler
Institutions
- Lund University (SE)
- Washington University in St. Louis (US)
- Science for Life Laboratory (SE)
- Pasqual Maragall Foundation (ES)
- Amsterdam Neuroscience (NL)
- Hope Center for Neurological Disorders (US)
- Barcelonaβeta Brain Research Center (ES)
- Prevent Alzheimer’s Disease 2020 (US)
- Skåne University Hospital (SE)
- Amsterdam University Medical Centers (NL)
- Eisai (Japan) (JP)
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_098889
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00